Because GLUT3 expression is mainly restricted to the brain of healthy individuals, the future development of small molecule compounds that selectively block GLUT3 and that do not cross the blood-brain barrier may become a viable strategy to treat patients with NSCLC and possibly other cancer types. This evidence concerns the gene SLC2A3 and non-small cell lung carcinoma.